Matica Bio, Cirsium Biosciences Enter AAV Manufacturing Pact

Matica Biotechnology, Inc., a CDMO specializing in viral vector production, and Cirsium Biosciences, a biotechnology company developing a plant-based AAV (adeno-associated virus) technology, entered a non-exclusive strategic partnership.

This collaboration leverages Cirsium’s hybrid hub-and-spoke manufacturing model, which combines internal plant-based AAV production capabilities with downstream collaborators to maximize flexibility, scalability, and distribution. Through this agreement, Matica Bio becomes an early adopter and partner, providing analytical and downstream support that complements Cirsium’s technology.

The cost and efficiency of AAV manufacturing remain significant constraints on gene therapy development and accessibility. Solutions that shorten production cycles and scale efficiently will be pivotal to sustaining industry growth. Together, Matica Bio and Cirsium aim to support more efficient manufacturing processes to enable rapid and more broad access to patients.

“Partnering with Cirsium means working alongside a company committed to advancing innovation in gene therapy,” said Paul Kim, CEO of Matica Bio. “We are proud to be an early partner in this decentralized model. Their innovative technology aligns seamlessly with our extensive capabilities in viral vector development and the manufacturing of clinical products. Together, we’re working to shape the future of next-generation treatments and expand availability to more patients.”

“Our hub-and-spoke model allows us to partner with leading organizations like Matica Bio to expand AAV manufacturing flexibility and scalability,” said Dr. Daniel Gibbs, CEO of Cirsium. “This collaboration reflects our mission to pursue more efficient approaches to gene therapy manufacturing.”